Hematology Partnering Terms andAgreementsThe Hematology Partnering Terms and Agreements report provides comprehensive unde...
Chapter 3 provides a review of the leading hematology deals since 2007. Deals are listed by headlinevalue, signed by bigph...
   Most active hematology dealmakers since 2007In Hematology Partnering Terms and Agreements, available deals and contrac...
Hematology Partnering Terms and Agreements provides the reader with the following keybenefits:      In-depth understandin...
Upcoming SlideShare
Loading in …5
×

Hematology partnering terms and agreements

214 views
182 views

Published on

The Hematology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the hematology partnering deals and agreements entered into by the worlds leading healthcare companies.

Published in: Health & Medicine, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
214
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Hematology partnering terms and agreements

  1. 1. Hematology Partnering Terms andAgreementsThe Hematology Partnering Terms and Agreements report provides comprehensive understanding andunprecedented access to the hematology partnering deals and agreements entered into by the worldsleading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter hematologypartnering deals. The majority of deals are discovery or development stage whereby the licensee obtainsa right or an option right to license the licensors infectives technology. These deals tend to bemulticomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight intothe negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilstmany smaller companies will be seeking details of the payments clauses, the devil is in the detail in termsof how payments are triggered – contract documents provide this insight where press releases do not.This report contains over 1,000 links to online copies of actual hematology deals and contract documentsas submitted to the Securities Exchange Commission by companies and their partners. Contractdocuments provide the answers to numerous questions about a prospective partner’s flexibility on a widerange of important issues, many of which will have a significant impact on each party’s ability to derivevalue from the deal. http://www.reportsnreports.com/reports/184087-Buy your copy of this report @hematology-partnering-terms-and-agreements.htmlReport Details:Published: September 2012No. of Pages: 630Price: Single User License: US$2695 Corporate User License: US$13475The initial chapters of this report provide an orientation of hematology dealmaking and business activities.Chapter 1 provides an introduction to the report.Chapter 2 provides an overview of the trends in hematology dealmaking since 2007 covering trends byyear, deal type, stage of development, technology type and therapeutic indication. In addition the chapterincludes an analysis of financial deal terms by stage at signing covering headline value, upfront payment,milestone payments and royalty rates. Analysis includes median values and distribution of values for eachstage of development.
  2. 2. Chapter 3 provides a review of the leading hematology deals since 2007. Deals are listed by headlinevalue, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Wherethe deal has an agreement contract published at the SEC a link provides online access to the contract.Chapter 4 provides a comprehensive listing of the top bigpharma companies with a brief summaryfollowed by a comprehensive listing of hematology deals, as well as contract documents available in thepublic domain. Where available, each deal title links via Weblink to an online version of the actualcontract document, providing easy access to each contract document on demand.Chapter 5 provides comprehensive access to all hematology deals since 2007 where a deal contract isavailable, providing the user with direct access to contracts as filed with the SEC regulatory authorities.Each deal title links via Weblink to an online version of the deal record contract document, providing easyaccess to each contract document on demand.Chapter 6 provides a comprehensive directory of all hematology partnering deals signed and announcedsince 2007. The chapter is organized by specific hematology therapy focus. Each deal title links viaWeblink to an online version of the deal record and where available, the contract document, providingeasy access to each contract document on demand.In addition, a comprehensive appendix is provided with each report of all hematology partnering dealssigned and announced since 2007. The appendices are organized by company A-Z, stage ofdevelopment at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type.Each deal title links via Weblink to an online version of the deal record and where available, the contractdocument, providing easy access to each contract document on demand.The report also includes numerous tables and figures that illustrate the trends and activities inhematology partnering and dealmaking since 2007.In conclusion, this report provides everything a prospective dealmaker needs to know about partnering inthe research, development and commercialization of hematology technologies and products.Report scopeHematology Partnering Terms and Agreements is intended to provide the reader with an in-depthunderstanding and access to hematology trends and structure of deals entered into by leading companiesworldwide.  Hematology Partnering Terms and Agreements includes:  Trends in hematology dealmaking in the biopharma industry since 2007  Analysis of hematology deal structure  Access to headline, upfront, milestone and royalty data  Access to hundreds of hematology deal contract documents  Comprehensive access to over 1,000 hematology deal records  The leading hematology deals by value since 2007
  3. 3.  Most active hematology dealmakers since 2007In Hematology Partnering Terms and Agreements, available deals and contracts are listed by:  Headline value  Upfront payment value  Royalty rate value  Stage of development at signing  Deal component type  Technology type  Specific therapy indicationEach deal title links via Weblink to an online version of the deal record and where available, the contractdocument, providing easy access to each contract document on demand.The Hematology Partnering Terms and Agreements report provides comprehensive access to availabledeals and contract documents for over 1,000 hematology deals.Analyzing actual contract agreements allows assessment of the following:  What are the precise hematology rights granted or optioned?  What is actually granted by the agreement to the partner company?  What exclusivity is granted?  What is the payment structure for the deal?  How aresalesand payments audited?  What is the deal term?  How are the key terms of the agreement defined?  How are IPRs handled and owned?  Who is responsible for commercialization?  Who is responsible for development, supply, and manufacture?  How is confidentiality and publication managed?  How are disputes to be resolved?  Under what conditions can the deal be terminated?  What happens when there is a change of ownership?  What sublicensing and subcontracting provisions have been agreed?  Which boilerplate clauses does the company insist upon?  Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?  Which jurisdiction does the company insist upon for agreement law?
  4. 4. Hematology Partnering Terms and Agreements provides the reader with the following keybenefits:  In-depth understanding of hematology deal trends since 2007  Access infectives deal headline, upfront, milestone and royalty data  Research hundreds of actual contracts between hematology partner companies  Comprehensive access to over 1,000 links to actual hematology deals entered into by the world’s biopharma companies  Indepth review of hematology deals entered into by the leading fifty bigpharma companies  Benchmark the key deal terms companies have agreed in previous deals  Identify key terms under which companies partner hematology opportunities  Uncover companies actively partnering hematology opportunitiesGet reports related to Pharmaceuticals Industry @ http://www.reportsnreports.com/market-research/pharmaceuticals/Contact sales@reportsandreports.com for further information.

×